Close
Blog & Resources Camargo Blog May 8th, 2009

505(b)(2) Combination Products

During the Q&A after my audioconference yesterday a participant asked if a proposed drug product containing 1 new drug and 2 already approved drugs would be a 505(b)(2). Although she didn’t say so, I assumed that the 2 approved drugs did not belong to her company.

The answer is yes, the inclusion of these 2 already known and approved drugs into a new combination is submitted as a 505(b)(2). In my response to the question, I used the example of the antihistamine Allegra – D (came easily to mind, my allergies are terrible this season). The ‘D’ in the name stands for the decongestant pseudoephedrine HCl. The sponsor used 505(b)(2) to gain approval. Aventis owned the NDA for Allegra (fexofenadine HCl) but not for pseudoephedrine. Aventis used the 505(b)(2) route to submit the safety & efficacy information for pseudoephedrine. Similarly, Pfizer used the 505(b)(2) route for its approval of its antihistamine with pseudoephedrine, Zyrtec D.

Remember, a sponsor still must meet the criteria under the combination drugs 21 CFR 300.50 – showing, for example, the independent contribution of each drug substance to the clinical effect. The FDA has extensive information on combination products at this site.


Categories: 505(b)(2) Development

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights